Despite our current knowledge of the role of BRAF V600E in primary tumor in tumorigenesis of PTC, considering tumor heterogeneity, the relationship between BRAF V600E and clinical characteristics should also be evaluated in metastases. The gene discussed is BRAF; the disease is neoplasm.